## Contents

Figure S1: Study population selection criteria for model development
Figure S2: Model validation cohort: Study population selection criteria4
Figure S3: Occurrence of cytopenia, myelotoxicity and renal function decline in sulfasalazine prescribed cohort
Figure S4: Occurrence of cytopenia, myelotoxicity and renal function decline in sulfasalazine prescribed cohort excluding patients prescribed either methotrexate, leflunomide, or thiopurines at cohort entry
Figure S5: Distribution of predicted risk in the model derivation cohort at 5 years7
Figure S6: Calibration of a prognostic model for SSZ discontinuation with abnormal monitoring blood-test results at 5-years in the development cohort <sup>1</sup>
Figure S7: Calibration of a prognostic model for SSZ discontinuation with abnormal monitoring blood-test results at 5-years in the validation cohort <sup>1</sup>
Figure S8: Distribution of predicted risk in the model validation cohort at 5 years10
Figure S9: Calibration of a prognostic model for SSZ discontinuation with abnormal monitoring blood-test results at 1 year in the validation cohort <sup>1</sup>
Figure S10: Calibration of a prognostic model for SSZ discontinuation with abnormal monitoring blood-test results at 2 years in the validation cohort <sup>1</sup>
Figure S11: Calibration of a prognostic model for SSZ discontinuation with abnormal monitoring blood-test results at 3 years in the validation cohort <sup>1</sup>
Figure S12: Calibration of a prognostic model for SSZ discontinuation with abnormal monitoring blood-test results at 4 years in the validation cohort <sup>1</sup>
Figure S13: Calibration of a prognostic model for SSZ discontinuation with abnormal monitoring blood-test results at 5 years in the validation cohort: stratified according to age. 15
Figure S14: Calibration of a prognostic model for SSZ discontinuation with abnormal monitoring blood-test results at 5 years in the validation cohort: stratified according to disease type

Decile	Age± (yr.)	Sex	BMI (kg/m²)	Alcohol	Disease	DM	CKD	Immune- suppress. drug	Statin	Anti- epileptic	Paracet amol	ΒΤΑ	Cumulative probability of outcome (%)
1	25-30	F	35.2	Moderate	PSA	No	No	MTX	No	No	No	No	5.25
2	35-40	М	23.0	Non- drinker	RA	No	No	No	No	No	No	No	6.19
3	25-30	F	21.6	Low	PSA	No	No	No	No	No	No	No	6.72
4	55-60	F	29.8	Low	RA	No	No	No	No	No	No	No	7.25
5	55-60	М	24.0	Non- drinker	RA	No	No	No	No	No	Yes	No	7.80
6	70-75	F	27.9	Low	RA	No	No	Aza/6-MP	No	Yes	Yes	No	8.45
7	45-50	F	25.3	Low	RA	No	No	MTX	No	No	No	No	9.29
8	75-80	М	27.7	Non- drinker	RA	Yes	No	No	Yes	No	Yes	No	10.52
9	65-70	М	30.6	Low	PSA	No	Yes	No	No	No	Yes	No	13.90
10	55-60	F	33.8	Non- drinker	RA	No	No	MTX	No	No	No	Yes	19.04

# Supplementary Table 1: Individual patient's characteristics at the midpoint of each decile of risk.

Aza/6-MP: - Azathioprine/6-Mercaptopurine; BMI: - Body Mass Index; BTA: - Blood Test abnormalities within 6 months of first primary care sulfasalazine prescription; CKD: - Chronic Kidney Disease; Anti-epileptics: - carbamazepine / valproate; DM: - diabetes mellitus; F: - female; M: - male; MTX: - methotrexate; PsA: - psoriatic arthritis; RA: - Rheumatoid Arthritis. ± 5-year age band. Exact age not shown for anonymity.

Figure S1: Study population selection criteria for model development





Figure S2: Model validation cohort: Study population selection criteria







Figure S3: Occurrence of cytopenia, myelotoxicity and renal function decline in the cohort exposed to sulfasalazine

Figure S4: Occurrence of cytopenia, myelotoxicity and renal function decline in sulfasalazine prescribed cohort excluding patients prescribed either methotrexate, leflunomide, or thiopurines at cohort entry








Figure S5: Distribution of predicted risk in the model derivation cohort at 5 years

Figure S6: Calibration of a prognostic model for SSZ discontinuation with abnormal monitoring blood-test results at 5-years in the development cohort<sup>1</sup>



<sup>1</sup>Data from a single imputed dataset; So(t=5) 0.940

Figure S7: Calibration of a prognostic model for SSZ discontinuation with abnormal monitoring blood-test results at 5-years in the validation cohort<sup>1</sup>



<sup>1</sup>Data from a single imputed dataset; So(t=5) 0.940





Figure S8: Distribution of predicted risk in the model validation cohort at 5 years

Figure S9: Calibration of a prognostic model for SSZ discontinuation with abnormal monitoring blood-test results at 1 year in the validation cohort<sup>1</sup>

#### A: Calibration plot




B: Smoothed calibration curve

<sup>1</sup>Data from a single imputed dataset was used;  $S_0(t_{=1})$  0.984

Figure S10: Calibration of a prognostic model for SSZ discontinuation with abnormal monitoring blood-test results at 2 years in the validation cohort<sup>1</sup>

A. Calibration plot



B. Smoothed calibration curve

<sup>1</sup>Data from a single imputed dataset was used;  $S_0(t_{=2})$  0.970

Figure S11: Calibration of a prognostic model for SSZ discontinuation with abnormal monitoring blood-test results at 3 years in the validation cohort<sup>1</sup>

25 Slope = 1.189 C-statistic = 0.666 <u>o</u> . S. 2 4 Observed .1 .15 observed risk .2 .3 Reference Groups 0 95% Cls ς. .05 0 0 .2 .3 predicted risk 0 .1 .5 .6 .4 .05 1 .15 Expected .25 0 .1 .2


B. Smoothed calibration curve

Data from a single imputed dataset was used;  $S_0(t_{=3})$  0.959

A. Calibration plot

Figure S12: Calibration of a prognostic model for SSZ discontinuation with abnormal monitoring blood-test results at 4 years in the validation cohort<sup>1</sup>

B. Smoothed calibration curve



#### A. Calibration plot

Data from a single imputed dataset was used;  $S_0(t_{=4})$  0.950

Figure S13: Calibration of a prognostic model for SSZ discontinuation with abnormal monitoring blood-test results at 5 years in the validation cohort: stratified according to age.

A. <60 years

B. ≥ 60 years




Figure S14: Calibration of a prognostic model for SSZ discontinuation with abnormal monitoring blood-test results at 5 years in the validation cohort: stratified according to disease type.

### A: Rheumatoid Arthritis

#### B: other inflammatory conditions

